PhaseBio Pharmaceuticals, Inc.
PHAS · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 5.86 | -0.01 | 0.06 | -0.00 |
| FCF Yield | -65.29% | -62.86% | -24.14% | -104.75% |
| EV / EBITDA | 25.73 | -0.84 | -2.86 | 1.87 |
| Quality | ||||
| ROIC | -0.35% | -208.23% | -52.02% | -33.61% |
| Gross Margin | 100.00% | 0.10% | 100.00% | 100.00% |
| Cash Conversion Ratio | 361.76 | 0.61 | 1.01 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | -83.38% | -21.75% | – | – |
| Free Cash Flow Growth | 18.37% | -51.33% | -136.16% | -102.62% |
| Safety | ||||
| Net Debt / EBITDA | -20.42 | 0.17 | 1.56 | 2.70 |
| Interest Coverage | 137.72 | -58.72 | -36.93 | -5.01 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -4,194.85 | 190.62 | 127.31 |